Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tensha banks $15M Series A to develop bromodomain inhibitor epigenetic drugs

This article was originally published in Scrip

Executive Summary

A Cambridge, Massachusetts-based biotech start-up with a new epigenetic approach, Tensha Therapeutics, has come out of stealth mode and announced it has gained a $15 million Series A financing round backed solely by HealthCare Ventures. The company, developing small molecule inhibitors of the BET family of bromodomain-containing proteins, was founded in July 2011, and had not raised any funding prior to this round.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts